Scientific publications
Criteria for preclinical models of cholangiocarcinoma: scientific and medical relevance
Diego F Calvisi 1, Luke Boulter 2 3, Javier Vaquero 4 5, Anna Saborowski 6, Luca Fabris 7 8, Pedro M Rodrigues 5 9 10, Cédric Coulouarn 11, Rui E Castro 12, Oreste Segatto 13, Chiara Raggi 14, Luc J W van der Laan 15, Guido Carpino 16, Benjamin Goeppert 17 18, Stephanie Roessler 19, Timothy J Kendall 20, Matthias Evert 1, Ester Gonzalez-Sanchez 4 5 21, Juan W Valle 22 23, Arndt Vogel 6, John Bridgewater 24, Mitesh J Borad 25, Gregory J Gores 26, Lewis R Roberts 26, Jose J G Marin 5 27, Jesper B Andersen 28, Domenico Alvaro 29, Alejandro Forner 5 30, Jesus M Banales 5 9 10 31, Vincenzo Cardinale 32, Rocio I R Macias 5 27, Silve Vicent 33 34 35, Xin Chen 36, Chiara Braconi 37, Monique M A Verstegen 15, Laura Fouassier 38; CCA Model Consortium
Abstract
Cholangiocarcinoma (CCA) is a rare malignancy that develops at any point along the biliary tree. CCA has a poor prognosis, its clinical management remains challenging, and effective treatments are lacking. Therefore, preclinical research is of pivotal importance and necessary to acquire a deeper understanding of CCA and improve therapeutic outcomes. Preclinical research involves developing and managing complementary experimental models, from in vitro assays using primary cells or cell lines cultured in 2D or 3D to in vivo models with engrafted material, chemically induced CCA or genetically engineered models. All are valuable tools with well-defined advantages and limitations. The choice of a preclinical model is guided by the question(s) to be addressed; ideally, results should be recapitulated in independent approaches. In this Consensus Statement, a task force of 45 experts in CCA molecular and cellular biology and clinicians, including pathologists, from ten countries provides recommendations on the minimal criteria for preclinical models to provide a uniform approach. These recommendations are based on two rounds of questionnaires completed by 35 (first round) and 45 (second round) experts to reach a consensus with 13 statements. An agreement was defined when at least 90% of the participants voting anonymously agreed with a statement. The ultimate goal was to transfer basic laboratory research to the clinics through increased disease understanding and to develop clinical biomarkers and innovative therapies for patients with CCA.
CITA DEL ARTÍCULO Nat Rev Gastroenterol Hepatol. 2023 Jul;20(7):462-480. doi: 10.1038/s41575-022-00739-y. Epub 2023 Feb 8.
Our authors
